A view of Dr. Reddy’s laboratory in Hyderabad.
Dr. Reddy’s Laboratories introduced on Saturday (June 13, 2026) that it will likely be the primary to launch Bosutinib tablets 400 mg, the generic equal of the anti-cancer drug Bosulif from Wyeth, a subsidiary of Pfizer, in the USA.
As a result of Bosutinib Tablets (400 mg) is a first-to-date product, it’s topic to 180 days of generic exclusivity for this indication in the USA, Dr. Reddys stated.
For this product, it had tied up with MSN Laboratories, one other generic drug maker primarily based in Hyderabad. Dr. Reddy’s has unique advertising and marketing rights for the product in the USA, however MSN is chargeable for creating and manufacturing the product, the corporate stated.
Citing information from IQVIA Nationwide Gross sales Views, the corporate introduced that U.S. gross sales for the Bosrif model (400mg) for the trailing 12 months ending April 2026 had been roughly $253.8 million.
“With this launch, we proceed to deal with strengthening our oncology portfolio and partnering throughout the well being system to make sure vital remedies are accessible and reasonably priced,” stated Dr. Reddy’s Milan Kalawadia CEO, North America.
The profitable improvement and commercialization of Bosutinib Tablets is a testomony to MSN’s robust scientific, regulatory and manufacturing capabilities in advanced oncology merchandise, stated Bharat Reddy, Government Director, MSN Laboratories.
Based on the US FDA, Boslif is a kinase inhibitor indicated for the remedy of grownup sufferers with newly identified persistent part Ph+ persistent myeloid leukemia (CML). Continual, superior, or blast part Ph+ CML with resistance or intolerance to earlier remedies.
